Reduction in proteinuria after immunosuppressive therapy and long-term kidney outcomes in patients with immunoglobulin A nephropathy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Despite controversy regarding the benefits of immunosuppressive therapy in immunoglobulin A nephropathy (IgAN), clinical outcomes may vary depending on the patient’s responsiveness to this therapy. This study evaluated long-term kidney outcomes according to the extent of proteinuria reduction after immunosuppression in IgAN patients. Methods: Among 927 patients with biopsy-proven IgAN, 127 patients underwent immunosuppression. Time-averaged urine protein-creatinine ratio before and within 1 year after start of immunosuppression were calculated, and responsiveness to immunosuppression was assessed as the reduction of proteinuria between the two periods. Patients were classified into tertiles according to the extent of proteinuria reduction. We compared the slopes of estimated glomerular filtration rate (eGFR) decline using a linear mixed model, and estimated hazard ratios (HRs) for disease progression (defined as development of a ≥ 30% decline in eGFR or end-stage renal disease) using a Cox proportional hazard model. Results: Median extent of proteinuria reduction was –2.1, –0.9, and –0.2 g/gCr in the first, second, and third tertiles, respectively. There were concomitant changes in the slopes of annual eGFR decline: –2.03, –2.44, and –4.62 mL/min/1.73 m2 among the first, second, and third tertiles, respectively. In multivariable Cox analysis, the HRs (95% confidence intervals) for disease progression were 0.30 (0.12 to 0.74) in the first tertile and 0.70 (0.34 to 1.45) in the second tertile compared with the thirdtertile. Conclusions: This study showed that greater proteinuria reduction after immunosuppression was associated with a lower risk of disease progression in patients with IgAN, suggesting that responsiveness to immunosuppression may be an important determinant of kidney outcomes.
Abstract
Background/Aims: Despite controversy regarding the benefits of immunosuppressive therapy in immunoglobulin A nephropathy (IgAN), clinical outcomes may vary depending on the patient’s responsiveness to this therapy. This study evaluated long-term kidney outcomes according to the extent of proteinuria reduction after immunosuppression in IgAN patients. Methods: Among 927 patients with biopsy-proven IgAN, 127 patients underwent immunosuppression. Time-averaged urine protein-creatinine ratio before and within 1 year after start of immunosuppression were calculated, and responsiveness to immunosuppression was assessed as the reduction of proteinuria between the two periods. Patients were classified into tertiles according to the extent of proteinuria reduction. We compared the slopes of estimated glomerular filtration rate (eGFR) decline using a linear mixed model, and estimated hazard ratios (HRs) for disease progression (defined as development of a ≥ 30% decline in eGFR or end-stage renal disease) using a Cox proportional hazard model. Results: Median extent of proteinuria reduction was –2.1, –0.9, and –0.2 g/gCr in the first, second, and third tertiles, respectively. There were concomitant changes in the slopes of annual eGFR decline: –2.03, –2.44, and –4.62 mL/min/1.73 m2 among the first, second, and third tertiles, respectively. In multivariable Cox analysis, the HRs (95% confidence intervals) for disease progression were 0.30 (0.12 to 0.74) in the first tertile and 0.70 (0.34 to 1.45) in the second tertile compared with the thirdtertile. Conclusions: This study showed that greater proteinuria reduction after immunosuppression was associated with a lower risk of disease progression in patients with IgAN, suggesting that responsiveness to immunosuppression may be an important determinant of kidney outcomes.
참고문헌 (34)
- Schena FP, "Epidemiology of IgA nephropathy : a global perspective", Semin Nephrol, 38, pp.435~442 (2018)
- D’Amico G, "The commonest glomerulonephritis in the world : IgA nephropathy", Q J Med, 64, pp.709~727 (1987)
- Schena FP, "A retrospective analysis of the natural history of primary IgA nephropathy worldwide", Am J Med, 89, pp.209~215 (1990)
- Donadio JV, "IgA nephropathy", N Engl J Med, 347, pp.738~748 (2002)
- Suzuki H, "Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity", J Clin Invest, 119, pp.1668~1677 (2009)
- Pozzi C, "Corticosteroids in IgA nephropathy : a randomised controlled trial", Lancet, 353, pp.883~887 (1999)
- Manno C, "Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy", Nephrol Dial Transplant, 24, pp.3694~3701 (2009)
- Lv J, "Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy : a randomized controlled trial", Am J Kidney Dis, 53, pp.26~32 (2009)
- Kidney disease: Improving global outcomes (KDIGO)glomerulonephritis work group, "KDIGO clinical practice guideline for glomerulonephritis", Kidney Int Suppl, 2, pp.139~274 (2012)
- Lv J, "Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy : the testing randomized clinical trial", JAMA, 318, pp.432~442 (2017)
- Rauen T, "Intensive supportive care plus immunosuppression in IgA nephropathy", N Engl J Med, 373, pp.2225~2236 (2015)
- Floege J, "Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference", Kidney Int, 95, pp.268~280 (2019)
- Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, "The Oxford classification of IgA nephropathy:rationale, clinicopathological correlations, and classification", Kidney Int, 76, pp.534~545 (2009)
- Chen T, "Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy", EBioMedicine, 52, pp.102657~ (2020)
- Le W, "Long-term renal survival and related risk factors in patients with IgA nephropathy : results from a cohort of 1155 cases in a Chinese adult population", Nephrol Dial Transplant, 27, pp.1479~1485 (2012)
- Reich HN, "Remission of proteinuria improves prognosis in IgA nephropathy", J Am Soc Nephrol, 18, pp.3177~3183 (2007)
- Mackinnon B, "Validation of the Toronto formula to predict progression in IgA nephropathy", Nephron Clin Pract, 109, pp.c148~c153 (2008)
- Nam KH, "Optimal proteinuria target for renoprotection in patients with IgA nephropathy", PLoS One, 9, pp.e101935~ (2014)
- Levey AS, "A new equation to estimate glomerular filtration rate", Ann Intern Med, 150, pp.604~612 (2009)
- Working Group of the International IgA Nephropathy Network, "The Oxford classification of IgA nephropathy : pathology definitions, correlations, and reproducibility", Kidney Int, 76, pp.546~556 (2009)
- Levey AS, "Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency", Am J Kidney Dis, 75, pp.84~104 (2020)
- D’Amico G, "Pathophysiology of proteinuria", Kidney Int, 63, pp.809~825 (2003)
- Gorriz JL, "Proteinuria : detection and role in native renal disease progression", Transplant Rev (Orlando), 26, pp.3~13 (2012)
- Nagata M, "Podocyte injury and its consequences", Kidney Int, 89, pp.1221~1230 (2016)
- Kannel WB, "The prognostic significance of proteinuria : the Framingham study", Am Heart J, 108, pp.1347~1352 (1984)
- Kobayashi Y, "IgA nephropathy : prognostic significance of proteinuria and histological alterations", Nephron, 34, pp.146~153 (1983)
- Barbour SJ, "Risk stratification of patients with IgA nephropathy", Am J Kidney Dis, 59, pp.865~873 (2012)
- Shi SF, "Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy : validation of the oxford classification", Clin J Am Soc Nephrol, 6, pp.2175~2184 (2011)
- Tesar V, "Corticosteroids in IgA nephropathy : a retrospective analysis from the VALIGA Study", J Am Soc Nephrol, 26, pp.2248~2258 (2015)
- Shen XH, "Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy : a repeat-biopsy based observation", J Nephrol, 28, pp.441~449 (2015)
- Thompson A, "Proteinuria reduction as a surrogate end point in trials of IgA nephropathy", Clin J Am Soc Nephrol, 14, pp.469~481 (2019)
- Berthoux F, "Predicting the risk for dialysis or death in IgA nephropathy", J Am Soc Nephrol, 22, pp.752~761 (2011)
- Trimarchi H, "Oxford classification of IgA nephropathy 2016 : an update from the IgA nephropathy classification working group", Kidney Int, 91, pp.1014~1021 (2017)
- "Treatment of IgA Nephropathy According to Renal Lesions (TIGER) study" (2019)[URL]